SARS-CoV-2使lentivirus

Junli Jia1, Emanuela Garbarino1, Yuhang Wang1,2

  • 1Department of Immunology, National Vaccine Innovation Platform, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, China.

PubMed
概括

科学家们开发了一种新方法来创建SARS-CoV-2尖端蛋白突变体,帮助开发适应性疗法来对抗像Omicron这样的不断变化的变体,并防止未来的流行病.

相关概念视频